The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-α-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
本技术提供的组合物包含与
氢吗啡酮(4,5-α-环氧-3-羟基-17-甲基
吗啡烷-6-酮)
化学共轭的芳基
羧酸,以形成新型的
氢吗啡酮原药/组合物。与未结合的
氢吗啡酮相比,本技术的
氢吗啡酮原药具有更低的副作用和更低的滥用可能性。本技术还提供了治疗病人的方法、医药包和合成本技术共轭物的方法。